| Lonza Group AG LONZA GROUP ORD SHS | 329.88 / -4.59% |
| Date/Time | 11/12 / 11:22 |
| Chg. / Chg.(%) | -15.86 / -4.59% |
| Bid | 297.60 / 5000 |
| Ask | 312.80 / 5000 |
| Open | 330.40 |
| Previous Close | 345.74 |
| High | 332.59 |
| Low | 327.30 |
| Volume [CHF] | 552,865.48 |
| Volume [Units] | 2,137 |
| Price fixings | 47 |
| ISIN | CH0013841017 |
| Security | 0QNO |
| Exchange | London International |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| SIX Swiss Ex.. | 329.10 |  |
474,564 |
| London Inter.. | 329.88 | |
2,137 |
| Lang & Schwa.. | 299.100 | |
|
| Nasdaq Other.. | 346.8700 | 2 | |
| Cboe Europe .. | 328.30 | 47,868 | |
| Turquoise | 328.30 |  |
18,782 |
| Cboe Europe .. | 328.00 | 12,923 | |
| TradeGate | 294.000 | 298 | |
| Stuttgart | 294.000 | 135 | |
| Frankfurt | 293.9000 | 63 | |
| Düsseldorf | 291.20 | 0 | |
| München | 291.30 | 0 | |
| Berlin | 296.90 | 0 | |
| Hamburg | 291.30 | 0 | |
| gettex | 296.100 | ||
| Singapore | 79.97 | 500 | |
| EUREX | Options | ||
News
- Vaxart Hosting Key Opinion Leader Meeting on the Health Economics of Norovirus Disease
11/06/2019 / 14:00 - GlobeNewswire - Global Primary Cells Market Analysis, Trends, and Forecasts Report 2019
10/30/2019 / 11:17 - GlobeNewswire - Worldwide Cell Based Assay & High Content Screening Market Forecasts to 2024 - Candidate Growth, Immuno-oncology, Genomic Blizzard, Technology Convergence, The Insurance Effect
10/29/2019 / 11:55 - GlobeNewswire - Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
10/24/2019 / 15:34 - GlobeNewswire - Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy
10/17/2019 / 00:17 - GlobeNewswire
Real-time